D-ribose-L-cysteine prevents oxidative stress and cardiometabolic syndrome in high fructose high fat diet fed rats

Biomed Pharmacother. 2021 Oct:142:112017. doi: 10.1016/j.biopha.2021.112017. Epub 2021 Aug 13.


Cardiometabolic syndrome has been linked with dietary modification. Therefore, we investigated the effects of D-ribose-L-cysteine (DRLC) in rats fed with high fructose high fat (HFHF) diet. Twenty rats (n = 5), divided into 4 groups were concurrently exposed to HFHF and/or DRLC (250 mg/kg, p.o) during the 8 weeks study. The result showed that compared to control group, HFHF group had significant impairment in lipid and glucose homeostasis, increased cardiac xanthine oxidase, systolic blood pressure, heart rate, %body weight change and fluid intake. Also, there were significant reductions in HDL-C, cardiac (GPX, NO&GGT), feed intake and relative heart weight in the latter, relative to the former. However, there were no significant differences in most of the observed physical and biochemical changes in HFHF + DRLC group compared to control. DRLC alone did not disrupt the level of biomarkers. Conclusively, DRLC prevented the manifestation of oxidative stress and cardiometabolic syndrome in HFHF-diet fed rats.

Keywords: D-ribose-L-cysteine; High fat; High fructose; Metabolic syndrome; Oxidative stress.

MeSH terms

  • Animals
  • Blood Pressure / physiology
  • Cysteine / analogs & derivatives*
  • Cysteine / pharmacology
  • Diet, High-Fat / adverse effects
  • Fructose
  • Glucose / metabolism
  • Heart Rate / physiology
  • Lipid Metabolism / drug effects
  • Male
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / prevention & control*
  • Oxidative Stress / drug effects*
  • Rats
  • Rats, Wistar
  • Thiazolidines / pharmacology*
  • Xanthine Oxidase / metabolism


  • Thiazolidines
  • 2-(1',2',3',4'-tetrahydroxybutyl)thiazolidine-4-carboxylic acid
  • Fructose
  • Xanthine Oxidase
  • Glucose
  • Cysteine